English	French	Notes	Complete/Exclude
DIAGNOSITC INFORMATION			
HISTOLOGY (ICD-O)			
DIFFERENTIATION/GRADE			
GLEASON'S SCORE			
DIAGNOSTIC INFORMATION			
METHOD OF DIAGNOSIS:			
600  CLINICAL DX WITH BONE LESION			
601  CLINICAL DX BY RECTAL EXAM..			
603  INCIDENTAL FINDING IN TURP..			
604  NEEDLE ASPIRATION BIOPSY....			
605  NEEDLE BIOPSY, NOS..........			
606  PERINEAL BIOPSY.............			
607  TRANSRECTAL BIOPSY..........			
608  TRUS GUIDED BIOPSY..........			
609  TRANSURETHRAL RESECTION, NOS			
DATE OF INITIAL DIAGNOSIS.....: 			
611  BONE MARROW ASPIRATION......			
612  BONE SCAN...................			
615  CT SCAN OF PRIMARY SITE.....			
617  LIVER SCAN..................			
619  PELVIC LYMPH NODE DISSECTION			
TABLE III - STAGE OF DISEASE			
38  AJCC STAGE.....			
19  CLINICAL STAGED BY..			
88  AJCC STAGE.....			
89  PATHOLOGIC STAGED BY			
RADIATON THERAPY			
  TYPE OF SURGERY................: 			
  DATE OF SURGERY................: 			
  REASON FOR NO SURGERY..........: 			
  SURGICAL APPROACH..............: 			
624  RESEARCH PROTOCOL..............			
625  RADIATION THERAPY..............			
  DATE RADIATION THERAPY BEGAN...: 			
626  INTERSTITIAL RADIATION.........			
  INTERSTITIAL RADIATION ADMINISTERED:			
631    OTHER INTERSTITIAL, NOS......			
632  EXTERNAL RADIATION.............			
  EXTERNAL RADIATION ADMINISTERED:			
633    PROSTATE REGION ONLY.........			
634    PROSTATE/PELVIC NODES........			
635    PARA-AORTIC NODES............			
636    DISTANT METASTATIC SITES.....			
637    OTHER EXTERNAL SITES, NOS....			
  TOTAL RAD DOSE:			
639    PELVIC NODES.................			
640    PARA-AORTIC NODES............			
641  RESEARCH PROTOCOL..............			
HORMONE THERAPY:			
642  HORMONE THERAPY................			
  DATE HORMONE THERAPY BEGAN.....: 			
  HORMONES ADMINISTERED:			
645    PROGESTATIONAL AGENTS........			
646    LUTEINIZING HORMONE-RELEASING			
METHODS USED TO DIAGNOSE FIRST RECURRENCE			
71TYPE OF FIRST RECURRENCE........			
70DATE OF FIRST RECURRENCE........			
METHODS USED TO DIAGNOSE FIRST RECURRENCE:			
650  BONE SCAN.....................			
652  RECTAL EXAM WITH NEEDLE BIOSPY			
653  TUMOR MARKER ELEVATION........			
654  WEIGHT LOSS...................			
TABLE VI - SUBSEQUENT TREATMENT			
656REASON FOR SECOND COURSE OF THERAPY			
SUBSEQUENT SURGERY #			
TYPE OF SURGERY....................: 			
DATE OF SURGERY....................: 			
SUBSEQUENT RADIATION THERAPY #			
16RADIATION THERAPY..................			
DATE RADIATON THERAPY BEGAN........: 			
4INTERSTITIAL RADIATION.............			
9    OTHER INTERSTITIAL, NOS........			
10EXTERNAL RADIATION.................			
11    PROSTATE REGION ONLY...........			
12    PROSTATE & PELVIC NODES........			
13    PARA-AORTIC NODES..............			
14    DISTANT METASTATIC SITES.......			
15    OTHER EXTERNAL, NOS............			
18    PELVIC NODES...................			
19    PARA-AORTIC NODES..............			
SUBSEQUENT CHEMOTHERAPY #			
DATE CHEMOTHERAPY BEGAN............: 			
  DRUGS ADMINISTERED:			
SUBSEQUENT HORMONE THERAPY #			
26HORMONE THERAPY....................			
DATE HORMONE THERAPY BEGAN.........: 			
29    PROGESTATIONAL AGENTS..........			
30    LUTEINIZING HORMONE-RELEASING..			
ACCESSION/SEQUENCE NUMBER..........: 			
CLASS OF CASE......................: 			
ZIP CODE...........................: 			
BIRTHDATE..........................: 			
RACE...............................: 			
PRIMARY PAYER AT DIAGNOSIS.........: 			
DATE OF ADMISSION..................: 			
DATE OF DISCHARGE..................: 			
  CLINICAL DX WITH BONE LESION.....: 			
  CLINICAL DX BY RECTAL EXAM.......: 			
  INCIDENTAL FINDING IN TURP.......: 			
  NEEDLE ASPIRATION BIOPSY.........: 			
  NEEDLE BIOPSY, NOS...............: 			
  PERINEAL BIOPSY..................: 			
  TRANSRECTAL BIOPSY...............: 			
  TRUS GUIDED BIOPSY...............: 			
  TRANSURETHRAL RESECTION, NOS.....: 			
DATE OF INITIAL DIAGNOSIS..........: 			
  BONE MARROW ASPIRATION...........: 			
  BONE SCAN........................: 			
  CT SCAN OF PRIMARY SITE..........: 			
  LIVER SCAN.......................: 			
  PELVIC LYMPH NODE DISSECTION.....: 			
HISTOLOGY (ICD-O)..................: 			
DIFFERENTIATION/GRADE..............: 			
GLEASON'S SCORE....................: 			
  AJCC STAGE....................: 			
CLINICAL STAGE..................: 			
PATHOLOGIC STAGE.................: 			
Print Prostate PCE Data.			
PCE Studies of Cancer of the Prostate			
  REASON FOR NO SURGERY.............: 			
  SURGICAL APPROACH.................: 			
  RESEARCH PROTOCOL.................: 			
  DATE RADIATION THERAPY BEGAN......: 			
  INTERSTITIAL RADIATION............: 			
    OTHER INTERSTITIAL, NOS.........: 			
  EXTERNAL RADIATION................: 			
    PROSTATE REGION ONLY............: 			
    PROSTATE/PELVIC NODES...........: 			
    PARA-AORTIC NODES...............: 			
    DISTANT METASTATIC SITES........: 			
    OTHER EXTERNAL SITES, NOS.......: 			
    PELVIC NODES....................: 			
    RESEARCH PROTOCOL...............: 			
  HORMONE THERAPY...................: 			
  DATE HORMONE THERAPY BEGAN........: 			
    PROGESTATIONAL AGENTS...........: 			
    LUTEINIZING HORMONE-RELEASING...: 			
  BONE SCAN.........................: 			
  RECTAL EXAM WITH NEEDLE BIOSPY....: 			
  TUMOR MARKER ELEVATION............: 			
  WEIGHT LOSS.......................: 			
REASON FOR SECOND COURSE OF THERAPY: 			
RADIATION THERAPY..................: 			
INTERSTITIAL RADIATION.............: 			
    OTHER INTERSTITIAL, NOS........: 			
EXTERNAL RADIATION.................: 			
    PROSTATE REGION ONLY...........: 			
    PROSTATE & PELVIC NODES........: 			
    PARA-AORTIC NODES..............: 			
    DISTANT METASTATIC SITES.......: 			
    OTHER EXTERNAL, NOS............: 			
    PELVIC NODES...................: 			
CHEMOTHERAPY.......................: 			
HORMONE THERAPY....................: 			
    PROGESTATIONAL AGENTS..........: 			
    LUTEINIZING HORMONE-RELEASING..: 			
DATE OF LAST CONTACT OR DEATH.....: 			
VITAL STATUS......................: 			
CANCER STATUS.....................: 			
AUTOPSY...........................: 			
COMPLETED BY......................: 			
REVIEWED BY CANCER COMMITTEE......: 			
Checking for any duplicates in ICDO MORHOLOGY (#164.1) file...			
MARGINAL ZONE LYMPHOMA, NOS IN			
MARGINAL ZONE LYMPHOMA, NOS			
Converting file #165.5 pointers...			
CANNOT CONVERT POINTER IN ENTRY NUMBER: 			
Converting file #160 pointers...			
Converting file #169.1 pointers...			
Converting file #164.1 pointers...			
Converting file #164.2 pointers...			
.01///MARGINAL ZONE LYMPHOMA, NOS IN SITU			
.01///MARGINAL ZONE LYMPHOMA, NOS			
 Tumor Size...................: 			
 Lymph Node...................: 			
 Regional Lymph Nodes Examined: 			
 Regional Lymph Nodes Positive: 			
 SEER Summary Stage 2000......: 			
 Site of Distant Metastasis #1: 			
 Site of Distant Metastasis #2: 			
 Site of Distant Metastasis #3: 			
 Clinical Staging			
TNM edition: 			
Pathologic Staging			
TNM........: 			
 Stage Group: 			
Stage Group: 			
 Staged By..: 			
Staged By..: 			
 Lymphatic Vessel Invasion (L): 			
 Venous Invasion (V)..........: 			
 Other Stage..................: 			
Restaging primaries with an ICD0-TOPOGRAPHY of C21.0, C53.0 or C31.8 and a			
DATE DX > 12/31/91.			
Restaging 			
 primary for patient 			
 Reindexing ATX cross-reference...			
.01  USUAL OCCUPATION...........			
3  USUAL INDUSTRY.............			
38    TOBACCO HISTORY............			
.01  TYPE OF TOBACCO USER.......			
2  YR QUIT TOBACCO USE........			
39    ALCOHOL HISTORY............			
.01  TYPE OF ALCOHOL USER.......			
1  YRS OF ALCOHOL USE.........			
2  DRINKS PER DAY.............			
3  YR QUIT DRINKING...........			
43    FAMILY HISTORY OF CANCER...			
.01  FAMILY MEMBER WITH CANCER..			
 **NOTE** CLASS OF CASE = 4 (Dx/1st tx before ref date)			
 The @FAC (at this facility) fields will be stuffed to			
 match the primary treatment fields.			
0 (Dx here, 1st tx ew)			
3 (Dx ew, 1st tx ew)			
6 (Dx/1st tx in MD office)			
 **NOTE** CLASS OF CASE = 			
 appropriate value indicating that no treatment was given			
 at this facility.			
 SURGICAL DIAGNOSTIC AND STAGING PROCEDURES			
 Surgical Dx/Staging Proc.....: 			
 Surg Dx/Staging Proc @fac....: 			
 SURGICAL PROCEDURES (ROADS)			
 Pre-2003 cases require the following ROADS surgery items to be coded:			
 Surgery of primary.........(R): 			
 Surgical Approach..........(R): 			
 Surgery of primary @fac....(R): 			
 Scope of ln surgery........(R): 			
 Number of LN removed...... (R): 			
 Scope of ln surgery @fac...(R): 			
 Number of LN removed @fac..(R): 			
 Surg proc/other site.......(R): 			
 Surg proc/other site @fac..(R): 			
 SURGICAL PROCEDURES (FORDS)			
 Date of 1st Surgical Procedure: 			
 Surgery of primary.........(F): 			
 Surgery of primary @fac....(F): 			
 Surgical margins..............: 			
 Scope of ln surgery........(F): 			
 Scope of ln surgery @fac...(F): 			
 Surg proc/other site.......(F): 			
 Surg proc/other site @fac..(F): 			
 Date of surgical discharge....: 			
 Reason for no surgery.........: 			
 Date radiation started........: 			
 Location of radiation tx......: 			
 Radiation treatment volume....: 			
 Regional treatment modality...: 			
 Regional dose:cGy.............: 			
 Boost treatment modality......: 			
 Boost dose:cGy................: 			
 Number of txs to this volume..: 			
 Radiation/surgery sequence....: 			
 Date radiation ended..........: 			
 Reason for no radiation.......: 			
 SYSTEMIC THERAPY			
 Date systemic therapy started.: 			
 Hormone therapy...............: 			
 Hormone therapy @fac..........: 			
 Hema Trans/Endocrine Proc.....: 			
 OTHER TREATMENT			
 Other treatment...............: 			
 Other treatment @fac..........: 			
 PALLIATIVE PROCEDURE/PROTOCOL PARTICIPATION			
 Pain assessment...............: 			
 Palliative procedure..........: 			
 Palliative procedure @fac.....: 			
 Protocol eligibility status...: 			
 Protocol participation........: 			
 Year put on protocol..........: 			
Histology code is incompatible.			
NOTE: Papillary or Follicular			
IS PU00			
IS PD00			
The Accession Year is not 1996.			
The Class of Case code is not 1 or 2.			
Skin sites are only allowed for patients with dermatofibrosarcoma.			
8:Print Soft Tissue Sarcoma PCE			
Patient Care Evaluation Study of Soft Tissue Sarcoma			
FAMILY HISTORY OF SOFT TISSUE SARCOMA			
500FAMILY HISTORY OF SOFT TISSUE SARCOMA			
501PERSONAL HISTORY OF ANY CANCER.......			
HISTOLOGIC WORKUP			
OUTSIDE CONFIRMATION OF BIOPSY			
ADDNL GRADE CODING SYSTEM			
VALUE OF ADDNL CODING SYSTEM			
TABLE II- INITIAL DIAGNOSIS/CANCER IDENTIFICATION			
CLASS OF CLASS................:			
502  ANGIOGRAM OF PRIMARY........			
503  BONE MARROW ASPIRATE/BIOPSY.			
504  BONE SCAN...................			
506  CT SCAN OF CHEST............			
507  CT SCAN OF PRIMARY..........			
508  LIVER FUNCTION STUDIES......			
510  MRI OF PRIMARY..............			
511  MRI OF OTHER................			
HISTOLOGIC WORKUP:			
515  ELECTRON MICROSCOPY.........			
329  FLOW CYTOMETRY..............			
517  IN SITU HYBRIDIZATION.......			
BIOPSIES:			
  TYPE                          HISTOLOGY/BEHAVIOR/GRADE			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################